

Luigi Bartalena

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1651866/publications.pdf>

Version: 2024-02-01

309
papers

18,267
citations

12303

69
h-index

16127

124
g-index

331
all docs

331
docs citations

331
times ranked

6570
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of Gravesâ€™ hyperthyroidism: present and future. Expert Review of Endocrinology and Metabolism, 2022, 17, 153-166.	1.2	19
2	Teprotumumab for Gravesâ€™ orbitopathy and ototoxicity: moving problems from eyes to ears?. Journal of Endocrinological Investigation, 2022, 45, 1455-1457.	1.8	22
3	Current concepts regarding Gravesâ€™ orbitopathy. Journal of Internal Medicine, 2022, 292, 692-716.	2.7	37
4	Antithyroid drugs in Gravesâ€™ hyperthyroidism: differences between â€œblock and replaceâ€ and â€œtitrationâ€ regimes in frequency of euthyroidism and Gravesâ€™ orbitopathy during treatment. Journal of Endocrinological Investigation, 2021, 44, 371-378.	1.8	8
5	Change in newly diagnosed Gravesâ€™ disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression. Journal of Endocrinological Investigation, 2021, 44, 1707-1718.	1.8	24
6	The Virgin Mary with a small goiter breastfeeding the Child. Journal of Endocrinological Investigation, 2021, 44, 641-642.	1.8	2
7	A young lady with goiter by Mario Sironi (1885â€“1961). Journal of Endocrinological Investigation, 2021, 44, 207-208.	1.8	2
8	Comicsâ€™ representation of Gravesâ€™ orbitopathy, by Emil Ferris. Journal of Endocrinological Investigation, 2021, 44, 1799-1800.	1.8	0
9	The 2021 European Group on Gravesâ€™ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Gravesâ€™ orbitopathy. European Journal of Endocrinology, 2021, 185, G43-G67.	1.9	362
10	Identification of Two Different Phenotypes of Patients with Amiodarone-Induced Thyrotoxicosis and Positive Thyrotropin Receptor Antibody Tests. Thyroid, 2021, 31, 1463-1471.	2.4	4
11	Statins for Graves' orbitopathy: a new tool for prevention and treatment?. Lancet Diabetes and Endocrinology, the, 2021, 9, 726-727.	5.5	2
12	Response to comment by Smith on the 2021 EUGOGO guidelines. European Journal of Endocrinology, 2021, 185, L15-L16.	1.9	1
13	Pituitary disorders as wonders and curiosity in XVI Century. Journal of Endocrinological Investigation, 2020, 43, 551-552.	1.8	0
14	Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: a narrative review. Journal of Endocrinological Investigation, 2020, 43, 413-429.	1.8	26
15	Oral steroid prophylaxis for Gravesâ€™ orbitopathy after radioactive iodine treatment for Gravesâ€™ disease is not only effective, but also safe. Journal of Endocrinological Investigation, 2020, 43, 381-383.	1.8	12
16	Comparison Between Total Thyroidectomy and Medical Therapy for Amiodarone-Induced Thyrotoxicosis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 242-251.	1.8	36
17	Features and outcome of differentiated thyroid carcinoma associated with Gravesâ€™ disease: results of a large, retrospective, multicenter study. Journal of Endocrinological Investigation, 2020, 43, 109-116.	1.8	18
18	A thyroid nodule in a young Sicilian princess in 1900. Journal of Endocrinological Investigation, 2020, 43, 699-700.	1.8	4

#	ARTICLE	IF	CITATIONS
19	Cushing syndrome at the court of the infant of Spain in the eighteenth century?. Journal of Endocrinological Investigation, 2020, 43, 871-872.	1.8	0
20	Treatment of Gravesâ€™ hyperthyroidism with thionamides: a position paper on indications and safety in pregnancy. Journal of Endocrinological Investigation, 2020, 43, 257-265.	1.8	15
21	The multinodular goiter of the virtuous Roman matron Lucretia by Artemisia Gentileschi. Journal of Endocrinological Investigation, 2020, 43, 701-702.	1.8	2
22	Proposal for Standardization of Primary and Secondary Outcomes in Patients with Active, Moderate-to-Severe Gravesâ€™ Orbitopathy. European Thyroid Journal, 2020, 9, 3-16.	1.2	23
23	Immunological Drivers in Graves' Disease: NK Cells as a Master Switcher. Frontiers in Endocrinology, 2020, 11, 406.	1.5	23
24	Duration of Exposure to Thyrotoxicosis Increases Mortality of Compromised AIT Patients: the Role of Early Thyroidectomy. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3427-e3436.	1.8	13
25	Epidemiology, Natural History, Risk Factors, and Prevention of Gravesâ€™ Orbitopathy. Frontiers in Endocrinology, 2020, 11, 615993.	1.5	132
26	Methimazole Treatment and Acute Pancreatitis: Both Caution and Reassurance Are Needed. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4967-e4969.	1.8	7
27	The interplay between thyroid and liver: implications for clinical practice. Journal of Endocrinological Investigation, 2020, 43, 885-899.	1.8	71
28	The artistâ€™s wife with a simple nontoxic goiter. Journal of Endocrinological Investigation, 2020, 43, 1043-1044.	1.8	3
29	Asymmetry indicates more severe and active disease in Gravesâ€™ orbitopathy: results from a prospective cross-sectional multicentre study. Journal of Endocrinological Investigation, 2020, 43, 1717-1722.	1.8	15
30	Treatment of moderate-to-severe and active Gravesâ€™ orbitopathy: a step forward from the OPTIC study. Journal of Endocrinological Investigation, 2020, 43, 1523-1525.	1.8	5
31	Gravesâ€™ orbitopathy represented as feature of a state of mind. Journal of Endocrinological Investigation, 2020, 43, 1343-1344.	1.8	2
32	Effect of high-dose intravenous glucocorticoid therapy on serum thyroid hormone concentrations in type 2 amiodarone-induced thyrotoxicosis: an exploratory study. Journal of Endocrinological Investigation, 2020, 43, 1637-1643.	1.8	13
33	Management of Gravesâ€™ hyperthyroidism and orbitopathy in time of COVID-19 pandemic. Journal of Endocrinological Investigation, 2020, 43, 1149-1151.	1.8	19
34	When primary hyperparathyroidism comes as good news. Endocrinology, Diabetes and Metabolism Case Reports, 2020, 2020, .	0.2	2
35	Serum Thyroid Hormone-Binding Proteins. , 2019, , 442-447.		3
36	Can a patient-tailored treatment approach for Graves' disease reduce mortality?. Lancet Diabetes and Endocrinology,the, 2019, 7, 245-246.	5.5	7

#	ARTICLE	IF	CITATIONS
37	The clinical enigma of the "Flea catcher" by Georges de La Tour: a pregnant sinner with pre-eclampsia or a hypothyroid girl?. Journal of Endocrinological Investigation, 2019, 42, 995-996.	1.8	1
38	Acromegaly in digital art. Journal of Endocrinological Investigation, 2019, 42, 1387-1388.	1.8	2
39	Can combination of glucocorticoids with other immunosuppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves' orbitopathy?. Journal of Endocrinological Investigation, 2019, 42, 351-352.	1.8	6
40	Graves' Ophthalmopathy. , 2019, , 323-337.		1
41	Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?. European Journal of Endocrinology, 2019, 181, D27-D43.	1.9	19
42	Iodine supplementation in women of reproductive age: a survey of clinical practice among Italian gynecologists and midwives. Journal of Endocrinological Investigation, 2019, 42, 353-355.	1.8	2
43	Happy Birthday, Journal of Endocrinological Investigation!. Journal of Endocrinological Investigation, 2018, 41, 1-1.	1.8	2
44	Management of Subclinical Hypothyroidism in Pregnancy: A Comment from the Italian Society of Endocrinology and the Italian Thyroid Association to the 2017 American Thyroid Association Guidelines "The Italian Way". Thyroid, 2018, 28, 551-555.	2.4	24
45	Predictive score for the development or progression of Graves' orbitopathy in patients with newly diagnosed Graves' hyperthyroidism. European Journal of Endocrinology, 2018, 178, 635-643.	1.9	59
46	Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes and Endocrinology, the, 2018, 6, 287-298.	5.5	128
47	2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. European Thyroid Journal, 2018, 7, 55-66.	1.2	165
48	Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management. Journal of Endocrinological Investigation, 2018, 41, 1425-1432.	1.8	54
49	2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. European Thyroid Journal, 2018, 7, 167-186.	1.2	544
50	Graves' Orbitopathy: do not give it for granted. Endocrine, 2018, 62, 731-732.	1.1	1
51	Treatment of Graves' Disease. Endocrinology, 2018, , 489-511.	0.1	0
52	Smoking and the Thyroid. , 2018, , 719-722.		0
53	Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?. Journal of Endocrinological Investigation, 2017, 40, 547-553.	1.8	57
54	Physical performance in newly diagnosed hypothyroidism: a pilot study. Journal of Endocrinological Investigation, 2017, 40, 1099-1106.	1.8	14

#	ARTICLE	IF	CITATIONS
55	Selenium in the Treatment of Thyroid Diseases. <i>European Thyroid Journal</i> , 2017, 6, 113-114.	1.2	9
56	Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 885-887.	1.8	17
57	General Management Plan for Graves' Orbitopathy. , 2017, , 105-112.		0
58	Cardiometabolic healthy and unhealthy obesity: does vitamin D play a role?. <i>Endocrine Connections</i> , 2017, 6, 943-951.	0.8	17
59	Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 72.	1.2	113
60	Maria Carolina of Austria, Queen of Naples and Sicily: a possible case of Graves' orbitopathy. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 239-240.	1.8	1
61	Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 281-287.	1.8	50
62	Macular Hole Surgery: The Healing Process of Outer Retinal Layers to Visual Acuity Recovery. <i>European Journal of Ophthalmology</i> , 2017, 27, 235-239.	0.7	24
63	The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. <i>European Thyroid Journal</i> , 2016, 5, 9-26.	1.2	738
64	The phenotype of newly diagnosed Graves' disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 1445-1451.	1.8	51
65	Recommendations for treatment of hypothyroidism with levothyroxine and levotriiodothyronine: a 2016 position statement of the Italian Society of Endocrinology and the Italian Thyroid Association. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 1465-1474.	1.8	36
66	Management of hyperthyroidism due to Graves' disease: frequently asked questions and answers (if) Tj ETQq0 0.0 rgBT /Overlock 10	1.8	64
67	Masked hypertension in newly diagnosed hypothyroidism: a pilot study. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 1131-1138.	1.8	19
68	A 2013 European survey of clinical practice patterns in the management of Graves' disease. <i>Clinical Endocrinology</i> , 2016, 84, 115-120.	1.2	148
69	The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 585-591.	1.8	24
70	Cigarette smoking: number one enemy for Graves ophthalmopathy. <i>Polish Archives of Internal Medicine</i> , 2016, 126, 725-726.	0.3	15
71	Treatment of Graves' Disease. <i>Endocrinology</i> , 2016, , 1-24.	0.1	0
72	Treatment of Hyperthyroidism in Patients with Graves' Orbitopathy. , 2015, , 213-222.		0

#	ARTICLE	IF	CITATIONS
73	Effects of treatment modalities for Gravesâ€™™ hyperthyroidism on Gravesâ€™™ orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement. Journal of Endocrinological Investigation, 2015, 38, 481-487.	1.8	44
74	Eyelid myiasis caused by <i>Cordylobia anthropophaga</i> . Ocular Immunology and Inflammation, 2015, 23, 259-260.	1.0	3
75	PREGO (presentation of Gravesâ€™™ orbitopathy) study: changes in referral patterns to European Group On Gravesâ€™™ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. British Journal of Ophthalmology, 2015, 99, 1531-1535.	2.1	92
76	Outcome Prediction of Treatment of Gravesâ€™™ Hyperthyroidism with Antithyroid Drugs. Hormone and Metabolic Research, 2015, 47, 767-772.	0.7	34
77	The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. European Thyroid Journal, 2015, 4, 149-163.	1.2	225
78	Amiodaron i tarczycy. Endokrynologia Polska, 2015, 66, 176-196.	0.3	32
79	Gravesâ€™™-like orbitopathy: do not forget IgG4-related disease. Journal of Endocrinological Investigation, 2014, 37, 1233-1235.	1.8	15
80	Vitreous Substitutes: The Present and the Future. BioMed Research International, 2014, 2014, 1-12.	0.9	86
81	What is the Role of Medical Therapy in the Management of Gravesâ€™™ Orbitopathy?. Acta Endocrinologica, 2014, 10, 249-258.	0.1	0
82	Steroid Prophylaxis After Radioiodine Treatment for Graves' Hyperthyroidism: Selective or Universal?. Thyroid, 2014, 24, 1441-1442.	2.4	5
83	Commentary. Ophthalmic Plastic and Reconstructive Surgery, 2014, 30, 420-423.	0.4	15
84	The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type. European Journal of Endocrinology, 2014, 171, 363-368.	1.9	43
85	Pituitary apoplexy during pregnancy: a rare, but dangerous headache. Journal of Endocrinological Investigation, 2014, 37, 789-797.	1.8	29
86	Extrathyroidal manifestations of Gravesâ€™™ disease: a 2014 update. Journal of Endocrinological Investigation, 2014, 37, 691-700.	1.8	198
87	Effects of Amiodarone, Thyroid Hormones and CYP2C9 and VKORC1 Polymorphisms on Warfarin Metabolism: A Review of the Literature. Endocrine Practice, 2013, 19, 1043-1049.	1.1	16
88	Diagnosis and management of Graves disease: a global overview. Nature Reviews Endocrinology, 2013, 9, 724-734.	4.3	215
89	Graves' Orbitopathy: Imperfect Treatments for a Rare Disease. European Thyroid Journal, 2013, 2, 259-269.	1.2	57
90	A teleconsultation network improves the efficacy of anti-VEGF therapy in retinal diseases. Journal of Telemedicine and Telecare, 2013, 19, 437-442.	1.4	16

#	ARTICLE	IF	CITATIONS
91	Prevalence and Natural History of Graves' Orbitopathy in a Large Series of Patients With Newly Diagnosed Graves' Hyperthyroidism Seen at a Single Center. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1443-1449.	1.8	253
92	Prevalence and natural history of Graves' orbitopathy in the XXI century. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 444-9.	1.8	70
93	Role of oxidative stress and selenium in Graves' hyperthyroidism and orbitopathy. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 15-20.	1.8	14
94	Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association. <i>European Journal of Endocrinology</i> , 2012, 166, 247-253.	1.9	112
95	Total Thyroidectomy in Patients with Amiodarone-Induced Thyrotoxicosis and Severe Left Ventricular Systolic Dysfunction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3515-3521.	1.8	58
96	Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 4454-4463.	1.8	282
97	Prevention of Graves'™ ophthalmopathy. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2012, 26, 371-379.	2.2	67
98	Amiodarone-induced thyrotoxicosis, an overview of <sc>UK</sc> management. <i>Clinical Endocrinology</i> , 2012, 77, 936-937.	1.2	8
99	Efficacy and Safety of Orbital Radiotherapy for Graves' Orbitopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3857-3865.	1.8	87
100	Treating Graves'™ orbitopathy: where are we?. <i>Endocrine</i> , 2012, 41, 167-168.	1.1	5
101	Amiodarone and the thyroid: a 2012 update. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 340-8.	1.8	66
102	Nodule size and fine-needle aspiration biopsy: diagnostic challenges for thyroid malignancy. <i>American Journal of Surgery</i> , 2011, 201, 525-530.	0.9	12
103	Selenium and the Course of Mild Graves' Orbitopathy. <i>New England Journal of Medicine</i> , 2011, 364, 1920-1931.	13.9	503
104	Continuation of Amiodarone Delays Restoration of Euthyroidism in Patients with Type 2 Amiodarone-Induced Thyrotoxicosis Treated with Prednisone: A Pilot Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3374-3380.	1.8	49
105	The Dilemma of How to Manage Graves' Hyperthyroidism in Patients with Associated Orbitopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 592-599.	1.8	94
106	The American Thyroid Association/American Association of Clinical Endocrinologists Guidelines for Hyperthyroidism and Other Causes of Thyrotoxicosis: A European Perspective. <i>Thyroid</i> , 2011, 21, 585-591.	2.4	74
107	What to do for moderate-to-severe and active Graves'™ orbitopathy if glucocorticoids fail?. <i>Clinical Endocrinology</i> , 2010, 73, 149-152.	1.2	22
108	Approach to the Patient with Amiodarone-Induced Thyrotoxicosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2529-2535.	1.8	166

#	ARTICLE	IF	CITATIONS
109	The Challenge of Orbital Decompression in a Patient with Multiple Autoimmune Diseases and Graves' Orbitopathy: A Case Report and Review of Literature. <i>Orbit</i> , 2010, 29, 48-50.	0.5	0
110	Lower Dose Prednisone Prevents Radioiodine-Associated Exacerbation of Initially Mild or Absent Graves' Orbitopathy: A Retrospective Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1333-1337.	1.8	117
111	Impact of Lithium on Efficacy of Radioactive Iodine Therapy for Graves' Disease: A Cohort Study on Cure Rate, Time to Cure, and Frequency of Increased Serum Thyroxine After Antithyroid Drug Withdrawal. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 201-208.	1.8	75
112	Analysis of voice in patients with untreated active acromegaly. <i>Journal of Endocrinological Investigation</i> , 2010, 33, 178-185.	1.8	10
113	Glucocorticoid administration for Graves' hyperthyroidism treated by radioiodine. A questionnaire survey among members of the European Thyroid Association. <i>Journal of Endocrinological Investigation</i> , 2010, 33, 409-413.	1.8	13
114	Novel treatment modalities for Graves' orbitopathy. <i>Pediatric Endocrinology Reviews</i> , 2010, 7 Suppl 2, 210-6.	1.2	1
115	Glucocorticoids Are Preferable to Thionamides as First-Line Treatment for Amiodarone-Induced Thyrotoxicosis due to Destructive Thyroiditis: A Matched Retrospective Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3757-3762.	1.8	51
116	Thyroid Autoimmunity and Environment. <i>Hormone and Metabolic Research</i> , 2009, 41, 436-442.	0.7	50
117	Plasma total and acylated Ghrelin concentrations in patients with clinical and subclinical thyroid dysfunction. <i>Journal of Endocrinological Investigation</i> , 2009, 32, 74-78.	1.8	18
118	Reduced colonic apoptosis in mice overexpressing bovine growth hormone occurs through changes in several kinase pathways. <i>Growth Hormone and IGF Research</i> , 2009, 19, 432-441.	0.5	5
119	Time interval in diagnosis and treatment of papillary thyroid cancer: a descriptive, retrospective study. <i>American Journal of Surgery</i> , 2009, 197, 434-438.	0.9	5
120	Graves' Ophthalmopathy. <i>New England Journal of Medicine</i> , 2009, 360, 994-1001.	13.9	287
121	Changes in the expression of suppressor of cytokine signalling (SOCS) 2 in the colonic mucosa of acromegalic patients are associated with hyperplastic polyps. <i>Clinical Endocrinology</i> , 2009, 70, 898-906.	1.2	9
122	Thyroid Hormone Treatment for Differentiated Thyroid Carcinoma: What Drug, How Long, What Dose?. <i>Current Cancer Therapy Reviews</i> , 2009, 5, 296-302.	0.2	0
123	Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists*. <i>Clinical Endocrinology</i> , 2008, 69, 812-818.	1.2	75
124	Relation between Graves' orbitopathy and radioiodine therapy for hyperthyroidism: facts and unsolved questions*. <i>Clinical Endocrinology</i> , 2008, 69, 845-847.	1.2	21
125	Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. <i>European Journal of Endocrinology</i> , 2008, 158, 273-285.	1.9	611
126	Declaración de consenso del Grupo europeo sobre la orbitopatía de Graves (EUGOGO) sobre el tratamiento de la orbitopatía de Graves (OG). <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2008, 55, 356.e1-356.e13.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Shortening hospital stay for thyroid surgery. <i>Expert Review of Medical Devices</i> , 2008, 5, 85-96.	1.4	3
128	Potassium perchlorate only temporarily restores euthyroidism in patients with amiodarone-induced hypothyroidism who continue amiodarone therapy. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 515-519.	1.8	14
129	Graves's hyperthyroidism of recent onset and Graves' orbitopathy: To ablate or not to ablate the thyroid?. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 578-581.	1.8	12
130	Identification, treatment and management of cardiovascular risks in patients with acromegaly. <i>Expert Review of Endocrinology and Metabolism</i> , 2008, 3, 603-614.	1.2	1
131	Amiodarone-induced thyrotoxicosis: something new to refine the initial diagnosis?. <i>European Journal of Endocrinology</i> , 2008, 159, 359-361.	1.9	25
132	Perspectives in pharmacological management of Graves' hyperthyroidism and orbitopathy. <i>Expert Review of Clinical Immunology</i> , 2008, 4, 321-329.	1.3	0
133	Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' Orbitopathy. <i>Thyroid</i> , 2008, 18, 333-346.	2.4	342
134	Novel Immunomodulating Agents for Graves Orbitopathy. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2008, 24, 251-256.	0.4	24
135	Hyperthyroidism Due to Graves' Disease – Is There an Optimal Pharmacological Treatment Regimen?. <i>European Endocrinology</i> , 2008, 4, 63.	0.8	0
136	Medullary thyroid carcinoma: surgical treatment advances. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 877-885.	1.1	15
137	Effects of Total Thyroid Ablation Versus Near-Total Thyroidectomy Alone on Mild to Moderate Graves' Orbitopathy Treated with Intravenous Glucocorticoids. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1653-1658.	1.8	121
138	Cardiac expression of adenine nucleotide translocase-1 in transgenic mice overexpressing bovine GH. <i>Journal of Endocrinology</i> , 2007, 194, 521-527.	1.2	7
139	Glucocorticoid Response in Amiodarone-Induced Thyrotoxicosis Resulting from Destructive Thyroiditis Is Predicted by Thyroid Volume and Serum Free Thyroid Hormone Concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 556-562.	1.8	70
140	Prevalence and Functional Significance of Antipituitary Antibodies in Patients with Autoimmune and Non-Autoimmune Thyroid Diseases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2176-2181.	1.8	74
141	Changes in Autonomic Modulation to the Heart and Intracellular Catecholamines. <i>Hormone Research in Paediatrics</i> , 2007, 67, 171-178.	0.8	6
142	Pain Perception, Blood Pressure Levels, and Peripheral Benzodiazepine Receptors in Patients Followed for Differentiated Thyroid Carcinoma: A Longitudinal Study in Hypothyroidism and During Hormone Treatment. <i>Clinical Journal of Pain</i> , 2007, 23, 518-523.	0.8	7
143	Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy. <i>Clinical Endocrinology</i> , 2007, 67, 070611013542001-???	1.2	47
144	Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study. <i>Thrombosis and Haemostasis</i> , 2007, 97, 803-6.	1.8	13

#	ARTICLE	IF	CITATIONS
145	Currently available somatostatin analogs are not good for Gravesâ€™ orbitopathy. Journal of Endocrinological Investigation, 2006, 29, 389-390.	1.8	6
146	Long-term outcome of thyroid function after amiodarone-induced thyrotoxicosis, as compared to subacute thyroiditis. Journal of Endocrinological Investigation, 2006, 29, 694-699.	1.8	45
147	Uptake of amiodarone by thyroidal and non-thyroidal cell lines. Journal of Endocrinological Investigation, 2006, 29, 61-66.	1.8	8
148	Immunotherapy for Gravesâ€™ orbitopathy: Easy enthusiasm, but letâ€™s keep trying. Journal of Endocrinological Investigation, 2006, 29, 1012-1016.	1.8	6
149	Thyroid hormone regulation of cell migration and oxidative metabolism in polymorphonuclear leukocytes: Clinical evidence in thyroidectomized subjects on thyroxine replacement therapy. Life Sciences, 2006, 78, 1071-1077.	2.0	24
150	Management of amiodarone-induced thyrotoxicosis in Latin America: an electronic survey. Clinical Endocrinology, 2006, 65, 433-438.	1.2	33
151	Abnormal expression of PPAR gamma isoforms in the subcutaneous adipose tissue of patients with Cushing's disease. Clinical Endocrinology, 2006, 66, 060904075417002-???	1.2	2
152	Identification of Acromegalic Patients at Risk of Developing Colonic Adenomas. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1351-1356.	1.8	48
153	The reduction of bone mineral density in postmenopausal women with primary hyperparathyroidism is higher in the presence of concomitant GH secretion impairment. European Journal of Endocrinology, 2006, 155, 41-45.	1.9	2
154	Thyroid Color Flow Doppler Sonography: An Adjunctive Tool for Differentiating Patients with Inappropriate Thyrotropin (TSH) Secretion Due to TSH-Secreting Pituitary Adenoma or Resistance to Thyroid Hormone. Thyroid, 2006, 16, 989-995.	2.4	17
155	Surgery of lymph nodes in papillary thyroid cancer. Expert Review of Anticancer Therapy, 2006, 6, 1217-1229.	1.1	24
156	Apoptosis is reduced in the colonic mucosa of patients with acromegaly. Clinical Endocrinology, 2005, 63, 683-688.	1.2	22
157	Glucocorticoids and outcome of radioactive iodine therapy for Gravesâ€™ hyperthyroidism. European Journal of Endocrinology, 2005, 153, 13-14.	1.9	18
158	Glucocorticoids for Gravesâ€™ Ophthalmopathy: How and When1. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5497-5499.	1.8	39
159	An update on the pharmacological management of hyperthyroidism due to Gravesâ€™ disease. Expert Opinion on Pharmacotherapy, 2005, 6, 851-861.	0.9	12
160	Thyroid function differently affects serum cystatin C and creatinine concentrations. Journal of Endocrinological Investigation, 2005, 28, 346-349.	1.8	172
161	Gravesâ€™ ophthalmopathy: Search for shared autoantigen(s) continues. Journal of Endocrinological Investigation, 2005, 28, 396-397.	1.8	4
162	Growth hormone secretion in primary and secondary hyperparathyroidism. Journal of Endocrinological Investigation, 2005, 28, 113-116.	1.8	8

#	ARTICLE	IF	CITATIONS
163	Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Gravesâ€™™ ophthalmopathy treated successfully with glucocorticoids themselves. Journal of Endocrinological Investigation, 2005, 28, 280-284.	1.8	46
164	An update on medical management of Gravesâ€™™ ophthalmopathy. Journal of Endocrinological Investigation, 2005, 28, 469-478.	1.8	44
165	Somatostatin Analogs for Gravesâ€™™ Ophthalmopathy: Do They Bounce Off like a Rubber Bullet?. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5908-5909.	1.8	21
166	PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. European Journal of Endocrinology, 2004, 150, 863-875.	1.9	37
167	Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association. Clinical Endocrinology, 2004, 61, 494-502.	1.2	78
168	Acute and Severe Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy in Patients with Graves' Ophthalmopathy. Thyroid, 2004, 14, 403-406.	2.4	151
169	La prevenzione dellâ€™™oftalmopatia basedowiana. L Endocrinologo, 2004, 5, 47-51.	0.0	0
170	Relationship between management of hyperthyroidism and course of the ophthalmopathy. Journal of Endocrinological Investigation, 2004, 27, 288-294.	1.8	41
171	Gravesâ€™™ ophthalmopathy: State of the art and perspectives. Journal of Endocrinological Investigation, 2004, 27, 295-301.	1.8	77
172	Mutations in the SLC26A4 (pendrin) gene in patients with sensorineural deafness and enlarged vestibular aqueduct. Journal of Endocrinological Investigation, 2004, 27, 430-435.	1.8	31
173	Serum prostate-specific antigen concentration is increased in acromegalic women. Journal of Endocrinological Investigation, 2004, 27, 643-647.	1.8	4
174	Improvement of Growth Hormone Deficiency in Patients with Primary Hyperparathyroidism after Parathyroidectomy: Results of a Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1213-1216.	1.8	10
175	Oxidative stress and Graves' ophthalmopathy: <i>In vitro</i> studies and therapeutic implications. BioFactors, 2003, 19, 155-163.	2.6	71
176	Orbital radiotherapy for Gravesâ€™™ ophthalmopathy: Useful or useless? Safe or dangerous?. Journal of Endocrinological Investigation, 2003, 26, 5-16.	1.8	39
177	Antithyroid drug treatment prior to radioiodine therapy for Gravesâ€™™ disease: Yes or no?. Journal of Endocrinological Investigation, 2003, 26, 174-176.	1.8	7
178	Colonic polyps of acromegalic patients are not associated with mutations of the peroxisome proliferator activated receptor Î³ gene. Journal of Endocrinological Investigation, 2003, 26, 1054-1058.	1.8	4
179	Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. Journal of Endocrinological Investigation, 2003, 26, 635-640.	1.8	62
180	Effects of a mixture of polychlorinated biphenyls (Aroclor 1254) on the transcriptional activity of thyroid hormone receptor. Journal of Endocrinological Investigation, 2003, 26, 972-978.	1.8	45

#	ARTICLE	IF	CITATIONS
181	The dilemma of non-thyroidal illness syndrome: to treat or not to treat?. Journal of Endocrinological Investigation, 2003, 26, 1162-1162.	1.8	14
182	Treatment of Type II Amiodarone-Induced Thyrotoxicosis by Either Iopanoic Acid or Glucocorticoids: A Prospective, Randomized Study. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1999-2002.	1.8	77
183	Changes in the Expression of the Peroxisome Proliferator-Activated Receptor β Gene in the Colonic Polyps and Colonic Mucosa of Acromegalic Patients. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3938-3942.	1.8	19
184	Long-Term Safety of Orbital Radiotherapy for Graves' Ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3561-3566.	1.8	105
185	The role of somatostatin analogs in the management of Graves' ophthalmopathy. Journal of Endocrinological Investigation, 2003, 26, 109-13.	1.8	3
186	Orbital Radiotherapy for Graves' Ophthalmopathy. Thyroid, 2002, 12, 245-250.	2.4	85
187	Thyroid vascularity is increased in patients with active acromegaly. Clinical Endocrinology, 2002, 57, 65-70.	1.2	16
188	Treatment with Lithium Prevents Serum Thyroid Hormone Increase after Thionamide Withdrawal and Radioiodine Therapy in Patients with Graves' Disease. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4490-4495.	1.8	69
189	GH Secretion Is Impaired in Patients with Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1961-1964.	1.8	22
190	Graves' ophthalmopathy: a preventable disease?. European Journal of Endocrinology, 2002, 146, 457-461.	1.9	69
191	Controversies in radioiodine therapy: relation to ophthalmopathy, the possible radioprotective effect of antithyroid drugs, and use in large goitres. European Journal of Endocrinology, 2002, 147, 1-11.	1.9	46
192	Radioiodine therapy and Graves' ophthalmopathy. Nuclear Medicine Communications, 2002, 23, 1143-1145.	0.5	2
193	Iopanoic acid rapidly controls Type I amiodarone-induced thyrotoxicosis prior to thyroidectomy. Journal of Endocrinological Investigation, 2002, 25, 176-180.	1.8	46
194	Primary hyperparathyroidism is associated with an impaired secretion of growth hormone but not of the other anterior pituitary hormones. Journal of Endocrinological Investigation, 2002, 25, RC7-RC9.	1.8	5
195	Smoking and Graves' disease. Journal of Endocrinological Investigation, 2002, 25, 402-402.	1.8	19
196	Epidemiology and Prevention of Graves' Ophthalmopathy. Thyroid, 2002, 12, 855-860.	2.4	390
197	Adjuvant Effect of Lithium on Radioiodine Treatment of Hyperthyroidism. Thyroid, 2002, 12, 1153-1154.	2.4	15
198	Management of thyroid eye disease. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, S458-S465.	3.3	23

#	ARTICLE	IF	CITATIONS
199	Amiodarone-induced thyrotoxicosis: a difficult diagnostic and therapeutic challenge*. Clinical Endocrinology, 2002, 56, 23-24.	1.2	49
200	Novel Approaches to the Management of Graves` Ophthalmopathy. Hormones, 2002, 1, 76-90.	0.9	15
201	The Various Effects of Amiodarone on Thyroid Function. Thyroid, 2001, 11, 511-519.	2.4	135
202	Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. Journal of Endocrinological Investigation, 2001, 24, 116-130.	1.8	179
203	Desethylamiodarone antagonizes the effect of thyroid hormone at the molecular level. European Journal of Endocrinology, 2001, 145, 59-64.	1.9	27
204	Comparison of the Effectiveness and Tolerability of Intravenous or Oral Glucocorticoids Associated with Orbital Radiotherapy in the Management of Severe Gravesâ€™ Ophthalmopathy: Results of a Prospective, Single-Blind, Randomized Study. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3562-3567.	1.8	232
205	The Effects of Amiodarone on the Thyroid*. Endocrine Reviews, 2001, 22, 240-254.	8.9	389
206	A novel mutation in the pendrin gene associated with Pendred's syndrome. Clinical Endocrinology, 2000, 52, 279-285.	1.2	26
207	Soluble interleukin-1 receptor antagonist concentration in patients with Graves' ophthalmopathy is neither related to cigarette smoking nor predictive of subsequent response to glucocorticoids. Clinical Endocrinology, 2000, 52, 647-651.	1.2	22
208	Management of Gravesâ€™ Ophthalmopathy: Reality and Perspectives*. Endocrine Reviews, 2000, 21, 168-199.	8.9	527
209	Pendrin does not increase sulfate uptake in mammalian COS-7 cells. Journal of Endocrinological Investigation, 2000, 23, 170-172.	1.8	12
210	Management of Graves' Ophthalmopathy: Reality and Perspectives. , 2000, 21, 168-199.		183
211	Thyroid vascularity and blood flow are not dependent on serum thyroid hormone levels: studies in vivo by color flow doppler sonography. European Journal of Endocrinology, 1999, 140, 452-456.	1.9	113
212	The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study. Clinical Endocrinology, 1999, 51, 503-508.	1.2	85
213	Is thyroxine during lithium therapy necessary?. Journal of Endocrinological Investigation, 1999, 22, 220-222.	1.8	11
214	The age of patients with thyrotoxicosis factitia in Italy from 1973 to 1996. Journal of Endocrinological Investigation, 1999, 22, 128-133.	1.8	26
215	Interleukin-6 Levels are not Increased in Women with Postpartum Thyroid Dysfunction. Thyroid, 1998, 8, 371-375.	2.4	15
216	Orbital Radiotherapy for Graves' Ophthalmopathy. Thyroid, 1998, 8, 439-441.	2.4	39

#	ARTICLE	IF	CITATIONS
217	Relation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy. <i>New England Journal of Medicine</i> , 1998, 338, 73-78.	13.9	644
218	Cigarette Smoking and Treatment Outcomes in Graves Ophthalmopathy. <i>Annals of Internal Medicine</i> , 1998, 129, 632.	2.0	243
219	Role of cytokines in the pathogenesis of the euthyroid sick syndrome. <i>European Journal of Endocrinology</i> , 1998, 138, 603-614.	1.9	84
220	Color Flow Doppler Sonography Rapidly Differentiates Type I and Type II Amiodarone-Induced Thyrotoxicosis. <i>Thyroid</i> , 1997, 7, 541-545.	2.4	173
221	Graves' hyperthyroidism and ophthalmopathy associated with pemphigus vulgaris: Onset of thyroid autoimmune disease during chronic low-dose glucocorticoid therapy. <i>Journal of Endocrinological Investigation</i> , 1997, 20, 155-157.	1.8	19
222	Treating severe Graves' ophthalmopathy. <i>Bailliere's Clinical Endocrinology and Metabolism</i> , 1997, 11, 521-536.	1.0	80
223	l-thyroxine directly affects expression of thyroid hormone-sensitive genes: regulatory effect of RXR β . <i>Molecular and Cellular Endocrinology</i> , 1997, 134, 23-31.	1.6	25
224	Adverse Effects of Thyroid Hormone Preparations and Antithyroid Drugs. <i>Drug Safety</i> , 1996, 15, 53-63.	1.4	88
225	Color flow doppler sonography in thyrotoxicosis factitia. <i>Journal of Endocrinological Investigation</i> , 1996, 19, 603-606.	1.8	49
226	Study of serum 3,5,3'-triiodothyronine sulfate concentration in patients with systemic non-thyroidal illness. <i>European Journal of Endocrinology</i> , 1996, 134, 45-49.	1.9	26
227	Circulating levels of anticonvulsant metabolites of progesterone in women with partial epilepsy in the intercritical phase. <i>Italian Journal of Neurological Sciences</i> , 1996, 17, 277-281.	0.1	5
228	Graves' Disease Occurring after Subacute Thyroiditis: Report of a Case and Review of the Literature. <i>Thyroid</i> , 1996, 6, 345-348.	2.4	59
229	Radioiodine and thyroid-associated ophthalmopathy. <i>Orbit</i> , 1996, 15, 197-203.	0.5	5
230	Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 2930-2933.	1.8	180
231	Cytokine antagonists: new ideas for the management of Graves' ophthalmopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 446-448.	1.8	23
232	Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 2930-2933.	1.8	160
233	Therapeutic controversies. Radioiodine may be bad for Graves' ophthalmopathy, but..... <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995, 80, 342-345.	1.8	27
234	Cigarette smoking and the thyroid. <i>European Journal of Endocrinology</i> , 1995, 133, 507-512.	1.9	108

#	ARTICLE	IF	CITATIONS
235	Circadian thyrotropin variations are preserved in normal pregnant women. <i>European Journal of Endocrinology</i> , 1995, 133, 71-74.	1.9	7
236	Percutaneous ethanol injection: what is its role in the management of nodular lesions of endocrine glands?. <i>European Journal of Endocrinology</i> , 1995, 132, 300-301.	1.9	6
237	Interleukin-6 and the thyroid. <i>European Journal of Endocrinology</i> , 1995, 132, 386-393.	1.9	37
238	Non-autoimmune hyperthyroidism associated with isolated bilateral ocular lymphoma mimicking Graves's disease with ophthalmopathy: A cause of misdiagnosis. <i>Journal of Endocrinological Investigation</i> , 1995, 18, 817-819.	1.8	9
239	Interleukin 6 effects on the pituitary-thyroid axis in the rat. <i>European Journal of Endocrinology</i> , 1994, 131, 302-306.	1.9	26
240	Serum interleukin-6 in amiodarone-induced thyrotoxicosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 78, 423-427.	1.8	129
241	Interleukin-6: a marker of thyroid-destructive processes?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 1424-1427.	1.8	64
242	Diagnosis of thyroid dysfunction: present and future. <i>Nuclear Medicine and Biology</i> , 1994, 21, 531-544.	0.3	1
243	Relationship of the increased serum interleukin-6 concentration to changes of thyroid function in nonthyroidal illness. <i>Journal of Endocrinological Investigation</i> , 1994, 17, 269-274.	1.8	84
244	Levothyroxine suppressive therapy: Harmful and useless or harmless and useful?. <i>Journal of Endocrinological Investigation</i> , 1994, 17, 675-677.	1.8	15
245	Serum interleukin-6 in amiodarone-induced thyrotoxicosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 78, 423-427.	1.8	103
246	Effects of thyroxine excess on peripheral organs. <i>Vienna Clinical Weekly</i> , 1994, 21, 60-5.	0.9	8
247	Increased serum interleukin-6 concentration in patients with subacute thyroiditis: relationship with concomitant changes in serum T4-binding globulin concentration. <i>Journal of Endocrinological Investigation</i> , 1993, 16, 213-218.	1.8	59
248	Studies on thyroxine-binding globulin. <i>Journal of Endocrinological Investigation</i> , 1993, 16, 353-371.	1.8	8
249	Octreotide treatment does not affect the size of most nonfunctioning pituitary adenomas. <i>Journal of Endocrinological Investigation</i> , 1993, 16, 541-543.	1.8	31
250	Relationship between nocturnal serum thyrotropin peak and metabolic control in diabetic patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993, 76, 983-987.	1.8	17
251	Thyroid hormone transport proteins. <i>Clinics in Laboratory Medicine</i> , 1993, 13, 583-98.	0.7	27
252	Variations in Thyroid Hormone Transport Proteins and Their Clinical Implications. <i>Thyroid</i> , 1992, 2, 237-245.	2.4	81

#	ARTICLE	IF	CITATIONS
253	Effects of interleukin-6 on the expression of thyroid hormone-binding protein genes in cultured human hepatoblastoma-derived (Hep G2) cells. <i>Molecular Endocrinology</i> , 1992, 6, 935-942.	3.7	23
254	Relationship Between Graves' Ophthalmopathy and Type of Treatment of Graves' Hyperthyroidism. <i>Thyroid</i> , 1992, 2, 171-178.	2.4	81
255	Iodine contamination in subjects admitted to a general hospital. <i>Journal of Endocrinological Investigation</i> , 1992, 15, 307-308.	1.8	5
256	Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism. <i>Journal of Endocrinological Investigation</i> , 1991, 14, 847-851.	1.8	26
257	Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. <i>Journal of Endocrinological Investigation</i> , 1991, 14, 853-860.	1.8	149
258	The Lack of Nocturnal Serum Thyrotropin Surge in Patients with Nontoxic Nodular Goiter May Predict the Subsequent Occurrence of Hyperthyroidism*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 73, 604-608.	1.8	17
259	The Nocturnal Serum Thyrotropin Surge is Abolished in Patients with Adrenocorticotropin (ACTH)-Dependent or ACTH-Independent Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 72, 1195-1199.	1.8	58
260	Thyroid function tests and diagnostic protocols for investigation of thyroid dysfunction. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 1991, 27, 531-9.	0.2	1
261	Recent Achievements in Studies on Thyroid Hormone-Binding Proteins*. <i>Endocrine Reviews</i> , 1990, 11, 47-64.	8.9	117
262	Lack of Nocturnal Serum Thyrotropin Surge after Surgery*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 70, 293-296.	1.8	52
263	Nocturnal Serum Thyrotropin (TSH) Surge and the TSH Response to TSH-Releasing Hormone: Dissociated Behavior in Untreated Depressives*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 71, 650-655.	1.8	72
264	The differentiation-inducing agent sodium butyrate produces divergent effects on albumin and thyroxine-binding globulin synthesis by human hepatoblastoma-derived (Hep G2) cells. <i>Journal of Endocrinological Investigation</i> , 1990, 13, 917-922.	1.8	8
265	Neuropsychological assessment in schoolchildren from an area of moderate iodine deficiency. <i>Journal of Endocrinological Investigation</i> , 1990, 13, 427-431.	1.8	59
266	Evaluation of thyroid function in patients with rapid-cycling and non-rapid-cycling bipolar disorder. <i>Psychiatry Research</i> , 1990, 34, 13-17.	1.7	52
267	Lack of nocturnal serum thyrotropin (TSH) surge in patients with chronic renal failure undergoing regular maintenance hemofiltration: a case of central hypothyroidism. <i>Clinical Nephrology</i> , 1990, 34, 30-4.	0.4	7
268	Studies on the occurrence of ophthalmopathy in Graves' disease. <i>European Journal of Endocrinology</i> , 1989, 120, 473-478.	1.9	127
269	Use of Corticosteroids to Prevent Progression of Graves' Ophthalmopathy after Radioiodine Therapy for Hyperthyroidism. <i>New England Journal of Medicine</i> , 1989, 321, 1349-1352.	13.9	296
270	More on smoking habits and Graves' ophthalmopathy. <i>Journal of Endocrinological Investigation</i> , 1989, 12, 733-737.	1.8	187

#	ARTICLE	IF	CITATIONS
271	Effects of the antileukemic drug L-asparaginase on sex hormone-binding globulin: studies in vivo and in vitro. <i>Journal of Endocrinological Investigation</i> , 1989, 12, 489-493.	1.8	1
272	Ontogeny of Pancreatic TRH Occurs Independently of Brain Development.. <i>Annals of the New York Academy of Sciences</i> , 1989, 553, 624-625.	1.8	0
273	Orbital decompression for severe Graves' ophthalmopathy. Results of a three-wall operative technique. <i>Journal of Neurosurgical Sciences</i> , 1989, 33, 323-7.	0.3	6
274	The effect of altered thyroid function on serum fructosamine concentrations. <i>Clinical Biochemistry</i> , 1988, 21, 179-181.	0.8	12
275	Absence of serum thyroid hormone autoantibodies in patients chronically treated with amiodarone. <i>Journal of Endocrinological Investigation</i> , 1988, 11, 323-325.	1.8	9
276	Free thyroxine values in dried blood spots on filter paper in newborns are related to both gestational age and birth body weight. <i>Journal of Endocrinological Investigation</i> , 1988, 11, 515-519.	1.8	4
277	Thyroxine uptake by human hepatoma cells from serum of patients submitted to long-term thyroxine suppressive therapy. <i>Journal of Endocrinological Investigation</i> , 1988, 11, 629-635.	1.8	1
278	Radioactive iodine thyroid uptake in patients with amiodarone-iodine-induced thyroid dysfunction. <i>European Journal of Endocrinology</i> , 1988, 119, 167-173.	1.9	57
279	Free Thyroxine and Free Triiodothyronine Measurement in Dried Blood Spots on Filter Paper by Column Adsorption Chromatography Followed by Radioimmunoassay. <i>Hormone and Metabolic Research</i> , 1988, 20, 293-297.	0.7	6
280	Factors Affecting Suppression of Endogenous Thyrotropin Secretion by Thyroxine Treatment: Retrospective Analysis in Athyreotic and Goitrous Patients*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1987, 64, 849-855.	1.8	68
281	Evaluation of the Nocturnal Serum Thyrotropin (TSH) Surge, as Assessed by TSH Ultrasensitive Assay, in Patients Receiving Long Term<sc>I</sc>-Thyroxine Suppression Therapy and in Patients with Various Thyroid Disorders*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1987, 65, 1265-1271.	1.8	48
282	Interaction of the thyrotropin receptor on rat FRTL-5 thyroid cells with thyrotropin and a thyrotropin-stimulating autoantibody from Graves' patients. <i>Biochemical and Biophysical Research Communications</i> , 1987, 143, 266-272.	1.0	7
283	Diagnosis of amiodarone-iodine-induced thyrotoxicosis(AIIT) associated with severe nonthyroidal illness. <i>Journal of Endocrinological Investigation</i> , 1987, 10, 589-591.	1.8	17
284	High prevalence of subacute thyroiditis during summer season in Italy. <i>Journal of Endocrinological Investigation</i> , 1987, 10, 321-323.	1.8	87
285	Serum TSH measurements by a sensitive enzyme immunoassay discriminate euthyroid from hyperthyroid subjects and avoid the need for TRH test during suppressive therapy with L-thyroxine. <i>Clinical Biochemistry</i> , 1987, 20, 197-200.	0.8	4
286	AMIODARONE IODINE-INDUCED HYPOTHYROIDISM: RISK FACTORS AND FOLLOW-UP IN 28 CASES. <i>Clinical Endocrinology</i> , 1987, 26, 227-237.	1.2	108
287	ORBITAL COBALT IRRADIATION COMBINED WITH RETROBULBAR OR SYSTEMIC CORTICOSTEROIDS FOR GRAVES' OPHTHALMOPATHY: A COMPARATIVE STUDY. <i>Clinical Endocrinology</i> , 1987, 27, 33-42.	1.2	122
288	Serum free thyroid hormones in subclinical hypothyroidism. <i>Journal of Endocrinological Investigation</i> , 1986, 9, 315-319.	1.8	9

#	ARTICLE	IF	CITATIONS
289	Role of autoimmune and familial factors in goiter prevalence. Studies performed in a moderately endemic area. Journal of Endocrinological Investigation, 1986, 9, 161-164.	1.8	30
290	Serum thyrotropin by ultrasensitive immunoradiometric assay and serum free thyroid hormones in pregnancy. Journal of Endocrinological Investigation, 1986, 9, 185-189.	1.8	35
291	HUMAN SERUM THYROTROPHIN MEASUREMENT BY ULTRASENSITIVE IMMUNORADIOMETRIC ASSAY AS A FIRST-LINE TEST IN THE EVALUATION OF THYROID FUNCTION. Clinical Endocrinology, 1986, 24, 141-148.	1.2	60
292	Changes in Radioimmunoassayable Prealbumin (TBPA) Serum Levels from Birth to Adulthood. Hormone and Metabolic Research, 1986, 18, 73-73.	0.7	7
293	Serum thyroid hormones and thyroid hormone binding proteins in patients with completed stroke. Annals of Clinical Research, 1986, 18, 203-7.	0.2	1
294	Thyroid autoimmunity and endemic goiter. Endocrinologia Experimentalis, 1986, 20, 49-56.	0.0	5
295	RECIPROCAL CHANGES OF SERUM THYROGLOBULIN AND TSH IN RESIDENTS OF A MODERATE ENDEMIC GOITRE AREA. Clinical Endocrinology, 1985, 23, 115-122.	1.2	56
296	Characterization of nascent and secreted thyroxine-binding globulin in cultured human hepatoma (Hep G2) cells. Journal of Biological Chemistry, 1984, 259, 13605-9.	1.6	16
297	Effect of tunicamycin and monensin on secretion of thyroxine-binding globulin by cultured human hepatoma (Hep G2) cells. Journal of Biological Chemistry, 1984, 259, 13610-4.	1.6	20
298	TSH-displacing activity versus TSH-binding inhibiting activity of immunoglobulins from patients with Graves' disease. Journal of Endocrinological Investigation, 1983, 6, 375-378.	1.8	5
299	Orbital Cobalt Irradiation Combined with Systemic Corticosteroids for Graves' Ophthalmopathy: Comparison with Systemic Corticosteroids Alone*. Journal of Clinical Endocrinology and Metabolism, 1983, 56, 1139-1144.	1.8	282
300	Polymorphism of Human Thyroxine-Binding Globulin. Journal of Clinical Endocrinology and Metabolism, 1983, 57, 1186-1192.	1.8	31
301	Studies on thyroid cell surface antigens using cultured human thyroid cells. Clinical and Experimental Immunology, 1982, 47, 336-44.	1.1	20
302	Measurement of thyroid cell surface antibodies by radioassay using human cultured thyroid cells. Journal of Endocrinological Investigation, 1981, 4, 439-444.	1.8	9
303	COMPARISON BETWEEN THYROID STIMULATING AND TSH-BINDING INHIBITING IMMUNOGLOBULINS OF GRAVES' DISEASE. Clinical Endocrinology, 1981, 15, 175-182.	1.2	74
304	Graves' disease and Turner's syndrome. Journal of Endocrinological Investigation, 1980, 3, 429-431.	1.8	11
305	Radio-receptor assay of TSH: its use to detect thyroid-stimulating immunoglobulins. Journal of Endocrinological Investigation, 1978, 1, 17-24.	1.8	36
306	Use of solubilized radioiodinated thyroid plasma membranes for purification of TSH-receptor by affinity chromatography. FEBS Letters, 1978, 88, 292-294.	1.3	3

#	ARTICLE	IF	CITATIONS
307	Dissociation of Responsiveness to Thyrotropin-Releasing Hormone and Thyroid Suppressibility Following Antithyroid Drug Therapy of Hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 1976, 43, 543-549.	1.8	21
308	Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity. Journal of Endocrinological Investigation, 0, , .	1.8	4
309	Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Gravesâ€™ Disease Hyperthyroidism During Methimazole Treatment. Frontiers in Endocrinology, 0, 13, .	1.5	17